AmpliPhi Biosciences announces positive FDA feedback for its clinical stage bacteriophage
AmpliPhi Biosciences announced the company has received positive feedback, via written response, from the FDA regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting. No additional clinical or nonclinical data are required to proceed with the proposed trials. September 18, 2018